Dr. John A. Stoukides, MD
Geriatric Medicine (Geriatric Medicine (Family Medicine) Physician)
1018 Waterman Ave
East Providence, RI 02914
Who else practices at this address →
Providence County includes mental health (6% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 186
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Tufts University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Geriatric Medicine (Family Medicine) Physician primary
RI license MD07851
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Miriam Hospital Providence, RI
- Roger Williams Medical Center Providence, RI
Medical groups
- Prospect Chartercare Rwmc, LLC (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 186
- Services billed
- 738
- Patients’ average age
- 83
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 252 | 47 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 93 | 48 |
| Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 59 | 54 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 57 | 55 |
| Hospital discharge day management, 30 minutes or less | 56 | 52 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 39 | 36 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 37 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 29 | 20 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | 28 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 18 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 4 companies. The companies reported $415,576 in research payments for these studies, mostly to the institutions running them.
- A phase 3, multicenter, randomized, double-blind study to investigate the efficacy and safety of brenipatide compared with placebo for the treatment of adult participants with alcohol use disorder (renew-ALC-2)
Eli Lilly and Company - A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc. - A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c. - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
Celgene Corporation - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
E.r. Squibb & Sons, L.l.c. - A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Eli Lilly and Company · Completed · NCT05063539 - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.